Artemisinin inhibits tumor lymphangiogenesis by suppression of vascular endothelial growth factor C

Pharmacology

Volumn 82, Issue 2, 2008, Pages 148-155

  Wang, Jun ^a   Zhang, Bicheng ^a,b   Guo, Yan ^a   Li, Guanghui ^a   Xie, Qichao ^a   Zhu, Bo ^a   Gao, Jianfei ^b   Chen, Zhengtang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

Author keywords

Artemisinin; Lewis lung carcinoma; Lymph node metastasis; Lymphangiogenesis; Vascular endothelial growth factor C

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ARTEMISININ; CYTOKINE; DIHYDROARTEMISININ; INTERLEUKIN 1BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; VASCULOTROPIN C;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; LEWIS CARCINOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; TUMOR VOLUME;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ARTEMISININS; CARCINOMA, LEWIS LUNG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; LUNG NEOPLASMS; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 49749127985     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000148261     Document Type: Article

References (28)

1. Sakao Y, Miyamoto H, Yamazaki A, Oh T, Fukai R, Shiomi K, Saito Y: Prognostic significance of metastasis to the highest mediastinal lymph node in nonsmall cell lung cancer. Ann Thorac Surg 2006;81:292-297.
2. Tobler NE, Detmar M: Tumor and lymph node lymphangiogenesis: impact on cancer metastasis. J Leukoc Biol 2006;80:691-696.
3. He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, Harding T, Jooss K, Takahashi T, Alitalo K: Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res 2005;65:4739-4746.
4. Renyi-Vamos F, Tovari J, Fillinger J, Timar J, Paku S, Kenessey I, Ostoros G, Agocs L, Soltesz I, Dome B: Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer. Clin Cancer Res 2005;11:7344-7353.
5. He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K: Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 2002;94:819-825.
6. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109.
7. Chen Z, Varney ML, Backora MW, Cowan K, Solheim JC, Talmadge JE, Singh RK: Downregulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival. Cancer Res 2005;65:9004-9011.
8. Tran TH, Dolecek C, Pham PM, Nguyen TD, Nguyen TT, Le HT, Dong TH, Tran TT, Stepniewska K, White NJ, Farrar J: Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet 2004;363:18-22.
9. Singh NP, Lai HC: Artemisinin induces apoptosis in human cancer cells. Anticancer Res 2004;24:2277-2280.
10. Moore JC, Lai H, Li JR, Ren RL, McDougall JA, Singh NP, Chou CK: Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat. Cancer Lett 1995;98:83-87.
11. Efferth T, Benakis A, Romero MR, Tomicic M, Rauh R, Steinbach D, Häfer R, Stamminger T, Oesch F, Kaina B, Marschall M: Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic Biol Med 2004;37:998-1009.
12. Chen HH, Zhou HJ, Fang X: Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol Res 2003;48:231-236.
13. Wang J, Guo Y, Zhang BC, Chen ZT, Gao JF: Induction of apoptosis and inhibition of cell migration and tube-like formation by dihydroartemisinin in murine lymphatic endothelial cells. Pharmacology 2007;80:207-218.
14. Wang J, Zhou H, Zheng J, Cheng J, Liu W, Ding G, Wang L, Luo P, Lu Y, Cao H, Yu S, Li B, Zhang L: Antimalarial artemisinin synergizes with antibiotics to protect against lethal live Escherichia coli challenge by decreasing proinflammatory cytokine release. Antimicrob Agents Chemother 2006;50:2420-2427.
15. Bobek V, Kolostova K, Pinterov D, Boubelik M, Jiang P, Yang M, Hoffman RM: Syngeneic lymph-node-targeting model of green fluorescent protein-expressing Lewis lung carcinoma. Clin Exp Metastasis 2004;21:705-708.
16. Li WD, Dong YJ, Tu YY, Lin ZB: Dihydroarteannuin ameliorates lupus symptom of BXSB mice by inhibiting production of TNF-alpha and blocking the signaling pathway NF-kappa B translocation. Int Immunopharmacol 2006;6:1243-1250.
17. Efferth T: Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin - from bench to bedside. Planta Med 2007;73:299-309.
18. Matsuo M, Sakurai H, Koizumi K, Saiki I: Curcumin inhibits the formation of capillary-like tubes by rat lymphatic endothelial cells. Cancer Lett 2007;251:288-295.
19. Wissmann C, Detmar M: Pathways targeting tumor lymphangiogenesis. Clin Cancer Res 2006;12:6865-6868.
20. Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, Voronov E: The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 2006;25:387-408.
21. Ristimäki A, Narko K, Enholm B, Joukov V, Alitalo K: Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J Biol Chem 1998;272:8413-8418.
22. Timoshenko AV, Rastogi S, Lala PK: Migration-promoting role of VEGF-C and VEGFC binding receptors in human breast cancer cells. Br J Cancer 2007;97:1090-1098.
23. Hsieh CY, Chen CA, Chou CH, Lai KP, Jeng YM, Kuo ML, Wei LH: Overexpression of Her-2/NEU in epithelial ovarian carcinoma induces vascular endothelial growth factor C by activating NF-kappa B: implications for malignant ascites formation and tumor lymphangiogenesis. J Biomed Sci 2004;11:249-259.
24. Chilov D, Kukk E, Taira S, Jeltsch M, Kaukonen J, Palotie A, Joukov V, Alitalo K: Genomic organization of human and mouse genes for vascular endothelial growth factor C. J Biol Chem 1997;272:25176-25183.
25. Ma FX, Han ZC: Akt signaling and its role in postnatal neovascularization. Histol Histopathol 2005;20:275-281.
26. Timoshenko AV, Chakraborty C, Wagner GF, Lala PK: COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. Br J Cancer 2006;94:1154-1163.
27. Franchi A, Massi D, Santucci M, Masini E, Degl'Innocenti DR, Magnelli L, Fanti E, Naldini A, Ardinghi C, Carraro F, Gallo O: Inducible nitric oxide synthase activity correlates with lymphangiogenesis and vascular endothelial growth factor-C expression in head and neck squamous cell carcinoma. J Pathol 2006;208:439-445.
28. Aldieri E, Atragene D, Bergandi L, Riganti C, Costamagna C, Bosia A, Ghigo D: Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF-κB activation. FEBS Lett 2003;552:141-144.